Ceftriaxone promotes the emergence of AmpC-overproducing Enterobacteriaceae in gut microbiota from hospitalized patients

  • Victoire de LastoursEmail author
  • Tiphaine Goulenok
  • François Guérin
  • Hervé Jacquier
  • Cindy Eyma
  • Françoise Chau
  • Vincent Cattoir
  • Bruno Fantin
Original Article


Epidemiological data suggest that ceftriaxone may promote the emergence of commensal AmpC-overproducing Enterobacteriaceae because of a high biliary excretion. We tested this hypothesis in hospitalized patients either treated by ceftriaxone alone or receiving no antibiotics. Hospitalized patients with no previous antibiotics or hospitalization in the last 3 months, treated only with ceftriaxone, were prospectively included. For each ceftriaxone-treated patient, a control patient receiving no antibiotics was included. Clinical data and stools were collected at T0 (before antibiotics) and T1 (at the end of ceftriaxone treatment or at discharge) and T2 (3–6 months after T1) for the ceftriaxone-treated patients and at T0 and T1 for control patients. Third-generation cephalosporin-resistant Enterobacteriaceae were detected, identified by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF), and characterized genetically. Clonal relatedness was evaluated by random amplified polymorphic DNA-polymerase chain reaction (RAPD-PCR). Fifteen ceftriaxone and 22 control patients were included. Patients’ characteristics did not differ. At T0, 2/15 ceftriaxone-treated versus 1/22 control patients carried third-generation cephalosporin-resistant Enterobacteriaceae (p = 0.6). At T1, 4/15 (27%) ceftriaxone-treated patients carried AmpC producers versus 0/22 control patients (p = 0.02). Additionally, two and three subjects carried extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae in the ceftriaxone and control groups, respectively (p = 1). At T2, three ceftriaxone-treated patients still carried AmpC-producing Enterobacteriaceae with the same RAPD profile as at T1. In hospitalized subjects with no other selective pressure, treatment by ceftriaxone alone promotes the gut colonization by AmpC-overproducing Enterobacteriaceae in over a quarter of patients, with a persistent carriage after the end of antibiotic exposure. The ecological impact of ceftriaxone should not be underestimated.



This work was presented as a poster at the 27th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID) meeting (Vienna, Austria, 22–25 April 2017).


The research leading to these results has received funding from the European Union (EU) FP7 health program Evolution and Transfer of Antibiotic Resistance (EvoTAR #282004).

Compliance with ethical standards

Conflict of interest

All authors declare they have no conflict of interest concerning this work.

Ethical approval

This work was approved by the French National Institutional Review Board (IRB 00008522; clinical trial: NCT02031588).

Informed consent

All patients gave informed consent, according to French Law and the approval from the French National Institutional Review Board (IRB 00008522).


  1. 1.
    Jacoby GA (2009) AmpC beta-lactamases. Clin Microbiol Rev 22:161–182. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Pitout JDD, Laupland KB (2008) Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159–166. CrossRefPubMedGoogle Scholar
  3. 3.
    Nordmann P, Naas T, Poirel L (2011) Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Grohs P, Kernéis S, Sabatier B, Lavollay M, Carbonnelle E, Rostane H et al (2014) Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime. J Antimicrob Chemother 69:786–789. CrossRefPubMedGoogle Scholar
  5. 5.
    Muller A, Lopez-Lozano JM, Bertrand X, Talon D (2004) Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother 54:173–177. CrossRefPubMedGoogle Scholar
  6. 6.
    Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S et al (2009) Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis 200:390–398. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    de Lastours V, Cambau E, Guillard T, Marcade G, Chau F, Fantin B (2012) Diversity of individual dynamic patterns of emergence of resistance to quinolones in Escherichia coli from the fecal flora of healthy volunteers exposed to ciprofloxacin. J Infect Dis 206:1399–1406. CrossRefPubMedGoogle Scholar
  8. 8.
    Drieux L, Brossier F, Sougakoff W, Jarlier V (2008) Phenotypic detection of extended-spectrum β-lactamase production in Enterobacteriaceae: review and bench guide. Clin Microbiol Infect 14:90–103. CrossRefPubMedGoogle Scholar
  9. 9.
    Dallenne C, Da Costa A, Decré D, Favier C, Arlet G (2010) Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother 65:490–495. CrossRefPubMedGoogle Scholar
  10. 10.
    Pérez-Pérez FJ, Hanson ND (2002) Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40:2153–2162CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Martin B, Garriga M, Hugas M, Aymerich T (2005) Genetic diversity and safety aspects of enterococci from slightly fermented sausages. J Appl Microbiol 98:1177–1190. CrossRefPubMedGoogle Scholar
  12. 12.
    de Lastours V, Chau F, Roy C, Larroque B, Fantin B (2014) Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone. J Antimicrob Chemother 69:3393–3400. CrossRefPubMedGoogle Scholar
  13. 13.
    Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U et al (2014) ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 20(Suppl 1):1–55. CrossRefPubMedGoogle Scholar
  14. 14.
    de Lastours V, Bleibtreu A, Chau F, Burdet C, Duval X, Denamur E et al (2014) Quinolone-resistant Escherichia coli from the faecal microbiota of healthy volunteers after ciprofloxacin exposure are highly adapted to a commensal lifestyle. J Antimicrob Chemother 69:761–768. CrossRefPubMedGoogle Scholar
  15. 15.
    Ruppé E, Armand-Lefèvre L, Estellat C, Consigny PH, El Mniai A, Boussadia Y et al (2015) High rate of acquisition but short duration of carriage of multidrug-resistant Enterobacteriaceae after travel to the tropics. Clin Infect Dis 61:593–600. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Victoire de Lastours
    • 1
    • 2
    Email author return OK on get
  • Tiphaine Goulenok
    • 2
  • François Guérin
    • 3
    • 4
  • Hervé Jacquier
    • 1
    • 5
  • Cindy Eyma
    • 1
  • Françoise Chau
    • 1
  • Vincent Cattoir
    • 3
    • 4
    • 6
  • Bruno Fantin
    • 1
    • 2
  1. 1.IAME, UMR-1137, INSERM and Université Paris Diderot, Sorbonne Paris Cité ParisFrance
  2. 2.Service de Médecine InterneHôpital Beaujon, APHPClichyFrance
  3. 3.Service de MicrobiologieCHU de CaenCaenFrance
  4. 4.Université de Caen Normandie, EA4655CaenFrance
  5. 5.Service de MicrobiologieHôpital Lariboisière, APHPParisFrance
  6. 6.Service de Bactériologie-Hygiène HospitalièreCHU de RennesRennesFrance

Personalised recommendations